NCT00984477View on ClinicalTrials.gov

Study to Investigate the Activity of AZD5122 When Given as a Single Dose to Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 30, 2009

Study Completion Date

November 30, 2009

Conditions
Healthy
Interventions
DRUG

AZD5122

A single dose of oral suspension

DRUG

Placebo

A single dose of oral suspension

DRUG

AZD5122

A single intravenous infusion

Trial Locations (1)

Unknown

Research Site, Nottinghamshire

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY